Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Many targeted NGS-based panels have recently been introduced to detect RNA fusions useful for prognosis and therapy selection in cancer. Understanding the lower limits of detection (LOD) and the reproducibility across the reportable range of these assays is important for clinical adoption and regulatory compliance. However, there are few tools available to assess LOD. We generated an RNA panel that represents decreasing levels of 16 different RNA fusions and exam skipping events compared to the total cellular RNA.

Sponsored by

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.